Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Stemcentrx
company
About
Stemcentrx provides pharmaceutical services.
- 101 - 250
Details
- Last Funding Type
- Series G
- Last Funding Money Raised
- $250M
- Industries
- Alternative Medicine,Biotechnology,Health Diagnostics,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Stemcentrx develops therapies that cure and significantly improve survival for cancer patients. It provides disease specific treatments that attack tumors at the roots. Brian Slingerland and Scott J. Dylla founded Stemcentrx in 2008, with its headquarters in South San Francisco in California. Stemcentrx operates as a subsidiary of AbbVie as of June 1, 2016.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$450M
Stemcentrx has raised a total of
$450M
in funding over 2 rounds. Their latest funding was raised on
Sep 9, 2015 from a Series G round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 9, 2015 | Series G | $250M | 1 | — | — | Detail |
| May 30, 2014 | Series F | $200M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Stemcentrx is funded by 1 investors.
Sequoia Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sequoia Capital
|
— | Series G |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
